News Releases

Allon Therapeutics Announces Overnight Marketed Equity Offering

VANCOUVER, B.C. – Allon Therapeutics Inc. (“Allon Therapeutics” or the “Company”) (TSX – “NPC”) is pleased to announce that it has filed today a short form preliminary prospectus in respect of an overnight marketed offering of units (the “Offering”), each unit being comprised of one common share ... Continue reading →

Allon's CEO presenting at Rodman and Renshaw Global Conference

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) President and CEO Gordon McCauley will present an update of the Company’s business progress on Tuesday, September 13 at the Rodman and Renshaw Annual Global Investment Conference in New York City. McCauley’s presentation will include an update... Continue reading →

Allon Therapeutics provides pivotal study update and Q2 operating results

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) today provided an update on progress in its pivotal clinical trial in progressive supranuclear palsy (PSP) and announced its unaudited operating results for the three months ended June 30, 2011. At this time, approximately 75% of the planned su... Continue reading →

Allon granted U.S. patent for davunetide as a treatment for schizophrenia

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced today that an important United States patent has been issued covering the method of use for the company’s lead product davunetide and its associated neuroprotective technology platform as a treatment for schizophrenia. Earlier U.S. p... Continue reading →

New human imaging data support the neuroprotective effects of Allons davunetide

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) today announced new findings that 12 weeks of treatment with the Company’s lead product davunetide appears to prevent cortical thinning of important parts of the brains of schizophrenia patients. Dr. Bruce Morimoto, Allon’s Vice-President of ... Continue reading →

← Older posts Newer posts →